Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Bicycle Therapeutics (BCYC) FCF Margin (2018 - 2025)

Historic FCF Margin for Bicycle Therapeutics (BCYC) over the last 8 years, with Q3 2025 value amounting to 612.3%.

  • Bicycle Therapeutics' FCF Margin rose 8924500.0% to 612.3% in Q3 2025 from the same period last year, while for Sep 2025 it was 4216.68%, marking a year-over-year increase of 75576900.0%. This contributed to the annual value of 13829.92% for FY2024, which is 126307300.0% down from last year.
  • Latest data reveals that Bicycle Therapeutics reported FCF Margin of 612.3% as of Q3 2025, which was up 8924500.0% from 2509.73% recorded in Q2 2025.
  • In the past 5 years, Bicycle Therapeutics' FCF Margin registered a high of 497.32% during Q3 2021, and its lowest value of 2509.73% during Q2 2025.
  • For the 5-year period, Bicycle Therapeutics' FCF Margin averaged around 598.47%, with its median value being 612.3% (2025).
  • As far as peak fluctuations go, Bicycle Therapeutics' FCF Margin tumbled by -26386500bps in 2021, and later soared by 10596900bps in 2022.
  • Over the past 5 years, Bicycle Therapeutics' FCF Margin (Quarter) stood at 1437.75% in 2021, then soared by 74bps to 378.06% in 2022, then skyrocketed by 177bps to 289.62% in 2023, then crashed by -89bps to 32.15% in 2024, then crashed by -2004bps to 612.3% in 2025.
  • Its FCF Margin stands at 612.3% for Q3 2025, versus 2509.73% for Q2 2025 and 871.75% for Q1 2025.